Pridopidine not checked

Prilenia · ACR16 · TV7820

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 3 trial completes
Trials
3 active
11 in total · 2 in the EU
Targets
 

What this is

How it works
How it works isn't classified yet
Tested for
Amyotrophic Lateral Sclerosis, Huntington Disease
Main trialPhase 3
“The goal of this clinical trial is to learn if the drug pridopidine works to treat amyotrophic lateral sclerosis in adults. It will also help to learn about the safety of pridopidine. The main question it aims to answer is: Does pridopidine slow disease progression of ALS? Researchers will compare pridopidine to a placebo (a look-alike substance that contains no drug) to see if pridopidine works to treat ALS. Participants will: Take pridopidine or a placebo by mouth every day for 48 weeks. Afterwards, all participants will take pridopidine for another 48 weeks. Visit the clinic once…”In the company’s words, NCT07322003 on ClinicalTrials.gov
Other names
ACR16 · TV7820

Other drugs for Amyotrophic Lateral Sclerosis

All 48 drugs for Amyotrophic Lateral Sclerosis

Coming up2

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials11

TrialPhaseCompletesWhat it tests
Phase 3Recruiting Mar 2028 Pridopidine Phase 3 Study to Evaluate Efficacy and Safety in ALS
Phase 3Recruiting Jun 2028 Pridopidine Phase 3 Study in Huntington's Disease
Phase 3Completed 14 Jun 2010 A Study of Treatment With Pridopidine (ACR16) in Participants With Huntington's Disease
Phase 3Completed 14 Mar 2023 PRidopidine's Outcome On Function in Huntington Disease, PROOF- HD
Phase 2Completed 26 Jul 2010 A Study of Pridopidine (ACR16) for the Treatment of Participants With Huntington's Disease
Phase 2Completed 16 Dec 2015 A Phase 2, to Evaluating the Safety and Efficacy of Pridopidine Vs Placebo for Symptomatic Treatment in Patients With Huntington's Disease
Phase 2Completed 5 Jan 2018 Open-label Extension Study of Pridopidine (ACR16) in the Symptomatic Treatment of Huntington Disease
Phase 2Terminated 12 Jan 2018 A Study Evaluating if Pridopidine is Safe, Efficacious, and Tolerable in Patients With Huntington's Disease
Phase 2Terminated 22 Jul 2020 A Study to Assess the Safety and Effectiveness of Pridopidine Compared to Placebo in the Treatment of Levodopa-Induced Dyskinesia in Patients With Parkinson's Disease
Phase 1Completed 9 Feb 2018 A Study to Evaluate Sigma-1 and Dopamine-2 Receptor Occupancy by Pridopidine in the Human Brain of Healthy Volunteers and in Patients With Huntington's Disease
Phase 3Authorised not given A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Pridopidine in Participants with Amyotrophic Lateral Sclerosis
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow Pridopidine

Following is part of Solo: you see every change to Pridopidine the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in